Barely Significant
← all excerpts

Fluvoxamine for fatigue in primary biliary cirrhosis and primary sclerosing cholangitis: a randomised controlled trial [ISRCTN88246634].

BMC Gastroenterol · 2004 · PMC481069 · PMID 15251034

Europe PMCDOI
1
hedged sentence
0.0400
closest p · 0.8× alpha
0.0400
boldest claim

The sentences

borderline significantp = 0.04actually significant
Per-protocol analysis (12 patients and 14 patients in the fluvoxamine and placebo group, respectively) of the same outcomes showed no significant differences except for a borderline significant difference in the general fatigue domain of the MFI in favour of the placebo group (p = 0.04).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.